

**Amendments to the Specification**

Please replace the paragraph at page 1, lines 6 through 10 with the following amended paragraph:

This application is a continuation of International Application No. PCT/US00/05163, filed March 1, 2000, which is a continuation-in-part of U.S. Application No. 09/465,691, filed December 17, 1999, now abandoned, which is a continuation of U.S. Application No. 09/260,953, filed March 2, 1999, now abandoned. The entire teachings of these applications are incorporated herein by reference.

Please replace the paragraph at page 6, lines 19 through page 7, line 10 with the following amended paragraph:

In a particular embodiment, the anti-TNF $\alpha$  antibody is a chimeric antibody. In a preferred embodiment, the anti-TNF $\alpha$  antibody is chimeric monoclonal antibody cA2 (or an antigen binding fragment thereof) or murine monoclonal antibody A2 (or an antigen binding fragment thereof), or has an epitopic specificity similar to that of chimeric antibody cA2, murine monoclonal antibody A2, or antigen binding fragments thereof, including antibodies or antigen binding fragments reactive with the same or a functionally equivalent epitope on human TNF $\alpha$  as that bound by chimeric antibody cA2 or murine monoclonal antibody A2, or antigen binding fragments thereof. Antibodies with an epitopic specificity similar to that of chimeric antibody cA2 or murine monoclonal antibody A2 include antibodies which can compete with chimeric antibody cA2 or murine monoclonal antibody A2 (or antigen binding fragments thereof) for binding to human TNF $\alpha$ . Such antibodies or fragments can be obtained as described above. Chimeric antibody cA2, murine monoclonal antibody A2 and methods of obtaining these antibodies are also described in Le *et al.*, U.S. Patent No. 5,656,272; Le *et al.*, U.S. Patent No. 5,698,195; U.S. Application No. 08/192,093 (filed February 4, 1994; now U.S. Patent No. 6,284,471); U.S. Patent No. 5,919,452; Le, J. *et al.*, International Publication No. WO 92/16553 (published October 1, 1992); Knight, D.M. *et al.*, *Mol. Immunol.*, 30:1443-1453 (1993); and Siegel, S.A. *et al.*, *Cytokine*, 7(1):15-25 (1995), which references are each entirely incorporated herein by reference. Chimeric antibody cA2 is also known as infliximab and REMICADE.